Refining the role of surgery in de novo stage IV breast cancer: the need for biomarkers and mechanistic insights.

CommentOn

Breast Cancer. 2025 Mar;32(2):426-433. doi: 10.1007/s12282-025-01675-w.

COI Statement

Declarations. Conflict of interest: K.M. is a fractional shareholder of Datar Genetics stock. K.M. has received honoraria for offering academic and clinical advice to Merit Medical and QMedical corporations. Furthermore, he owns shares in HCA Healthcare UK.

References:

• Tokunaga E, Koi Y, Tajiri W, Koga C, Ijichi H, Akiyoshi S, Kawasaki J, Nakamura Y, Taguchi K, Okamoto M. The impact of breast surgery and systemic therapy on the survival of patients with de novo stage IV breast cancer. Breast Cancer. 2025. https://doi.org/10.1007/s12282-025-01675-w . (Epub ahead of print. PMID: 39893610).
• Gera R, Chehade HELH, Wazir U, Tayeh S, Kasem A, Mokbel K. Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: a meta-analysis. Sci Rep. 2020;10(1):2952. https://doi.org/10.1038/s41598-020-59908-1 . (PMID:32076063; PMCID:PMC7031518).
• Zhang Q, Cai Z, Gerratana L, Davis AA, D’Amico P, Chawla A, Jacob S, Zhang Y, Jiao J, Qin W, Reduzzi C, Flaum L, Shah A, Gradishar WJ. Early evaluation of risk stratification and clinical outcomes for patients with advanced breast cancer through combined monitoring of baseline circulating tumor cells and DNA. Clin Cancer Res. 2024;30(16):3470–80. https://doi.org/10.1158/1078-0432.CCR-24-0535 . (PMID: 38829582).
• Piranlioglu R, Lee E, Ouzounova M, Bollag RJ, Vinyard AH, Arbab AS, Marasco D, Guzel M, Cowell JK, Thangaraju M, Chadli A, Hassan KA, Wicha MS, Celis E, Korkaya H. Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model. Nat Commun. 2019;10(1):1430. https://doi.org/10.1038/s41467-019-09015-1 . (PMID:30926774; PMCID:PMC6441000).